Bacci G, Picci P, Gherlinzoni F, Van Horn J R, Orlandi M, Normand A R, Manfrini M, Pignatti G, Campanacci M
Chemioterapia. 1986 Apr;5(2):140-3.
Sixty-five patients with high grade central localized osteosarcoma of the extremities were treated according to a neoadjuvant chemotherapy schedule that was comprised of two methotrexate (MTX) cycles (high or moderate dosage) i.v. followed by cisplatinum (CDP) (continuous i.a. infusion for 24 hours). Thirty-four "good" responders (necrosis greater than 90%) were divide in two groups for post-operative treatment. The first group was treated for a short period (4 weeks) with i.v. MTX-CDP; the second group was treated for a longer period (24 weeks) with i.v. MTX-CDP and also adriamycin. Patients in the second group had far better results than the patients in the first group (19/19 vs. 5/15 continuously disease-free patients). Our results following this protocol indicate that even if patients are "good" responders to this neoadjuvant chemotherapy they should not undergo a shortened post-operative treatment, and the protocol should include adriamycin.
65例四肢高级别中央型骨肉瘤患者按照新辅助化疗方案进行治疗，该方案包括两个静脉注射甲氨蝶呤（MTX）周期（高剂量或中等剂量），随后给予顺铂（CDP）（持续动脉内输注24小时）。34例“良好”反应者（坏死率大于90%）被分为两组进行术后治疗。第一组接受短期（4周）静脉注射MTX-CDP治疗；第二组接受长期（24周）静脉注射MTX-CDP以及阿霉素治疗。第二组患者的结果远优于第一组患者（持续无病患者分别为19/19和5/15）。我们按照该方案得出的结果表明，即使患者对这种新辅助化疗是“良好”反应者，他们也不应接受缩短的术后治疗，并且该方案应包括阿霉素。
